{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:25:36Z","timestamp":1787030736164,"version":"build-2736575974"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sphingosine-1-phosphate receptor modulators (S1PRMs) are an effective class of disease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS). While cardiac arrhythmias such as bradycardia and atrioventricular (AV) block are recognized class effects of S1PRMs, comparative real-world safety profiles across all four approved agents-particularly newer agents with limited post-marketing data-remain insufficiently characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective pharmacovigilance analysis using data from the FDA Adverse Event Reporting System (FAERS) from the fourth quarter of 2010 to the first quarter of 2024. Disproportionality analysis was performed using the Reported Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN) and Multi-item Gamma Poisson Shrinker (MGPS). Adverse events were classified using Standardised MedDRA Queries narrow-scope terms and Preferred Terms (PTs). Univariate logistic regression was used to explore the association between demographic factors and arrhythmia reporting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 2,059 arrhythmia-related adverse events associated with S1PRMs, including 1,860 cases for fingolimod, 153 for siponimod, 38 for ozanimod, and 8 for ponesimod. Patients aged 18\u201365 and female patients constituted the majority of reports. Disproportionality analysis based signal detection identified heart rate decreased, cardiac flutter, and extrasystoles as prominent signals across S1PRMs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This pharmacovigilance study provides a comparative real-world overview of arrhythmia-related adverse event signals across four approved S1PRMs. The findings are concordant with the cardiac effects anticipated from the known pharmacology of S1PRMs and reinforce the importance of cardiac monitoring during treatment initiation. As a disproportionality analysis of spontaneous reports, these results reflect statistical associations rather than causal relationships and should be regarded as hypothesis-generating; cross-drug comparisons are further influenced by differential reporting, market duration and cumulative exposure. These results may complement clinical trial data for informed risk-benefit assessment, particularly for newer S1PRMs with limited post-marketing surveillance data.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1882323","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:29:13Z","timestamp":1787027353000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiac arrhythmias associated with S1PRMs: a pharmacovigilance study based on real-world data"],"prefix":"10.3389","volume":"17","author":[{"given":"Siqi","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Army Medical University (Third Military Medical University)","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linli","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Army Medical University (Third Military Medical University)","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Army Medical University (Third Military Medical University)","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"B2","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1056\/NEJMoa1800149","article-title":"Trial of fingolimod versus interferon Beta-1a in pediatric multiple sclerosis","volume":"379","author":"Chitnis","year":"2018","journal-title":"N. Engl. Journal Medicine"},{"key":"B3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40265-020-01431-8","article-title":"Sphingosine 1-phosphate receptor modulator therapy for multiple sclerosis: differential downstream receptor signalling and clinical profile effects","volume":"81","author":"Chun","year":"2021","journal-title":"Drugs"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1177\/1352458520968811","article-title":"Atlas of MS 2020: informing global policy change","volume":"26","author":"Coetzee","year":"2020","journal-title":"Mult. Sclerosis Houndmills, Basingstoke, Engl."},{"key":"B5","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S1474-4422(16)00018-1","article-title":"Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial","volume":"15","author":"Cohen","year":"2016","journal-title":"Lancet. Neurology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1177\/1352458518789884","article-title":"Efficacy and safety of Ozanimod in multiple sclerosis: Dose-Blinded extension of a randomized phase II study","volume":"25","author":"Cohen","year":"2019","journal-title":"Mult. Sclerosis Houndmills, Basingstoke, Engl."},{"key":"B7","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/acn3.52017","article-title":"Sphingosine 1-phosphate receptor modulators in multiple sclerosis treatment: a practical review","volume":"11","author":"Coyle","year":"2024","journal-title":"Ann. Clinical Translational Neurology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.msard.2014.05.005","article-title":"First-dose effects of fingolimod: pooled safety data from three phase 3 studies","volume":"3","author":"DiMarco","year":"2014","journal-title":"Multiple Scler. Relat. Disord."},{"key":"B9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00011-018-1185-0","article-title":"A comprehensive review on the treatment approaches of multiple sclerosis: currently and in the future","volume":"68","author":"Gholamzad","year":"2019","journal-title":"Inflamm. Res. official J. Eur. Histamine Res. Soc. . [et al.]"},{"key":"B10","doi-asserted-by":"publisher","first-page":"20447","DOI":"10.1073\/pnas.1009968107","article-title":"Lymph node cortical sinus organization and relationship to lymphocyte egress dynamics and antigen exposure","volume":"107","author":"Grigorova","year":"2010","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"B11","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"The N. Engl. Journal of Medicine"},{"key":"B12","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41582-021-00556-y","article-title":"Apparent changes in the epidemiology and severity of multiple sclerosis","volume":"17","author":"Koch-Henriksen","year":"2021","journal-title":"Nature Reviews. Neurology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1177\/1352458512438456","article-title":"Sudden unexpected death on fingolimod","volume":"18","author":"Lindsey","year":"2012","journal-title":"Multiple Sclerosis (Houndmills, Basingstoke, England)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1001\/jama.2022.14236","article-title":"What is multiple sclerosis?","volume":"328","author":"Marcus","year":"2022","journal-title":"Jama"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/S0140-6736(21)00244-0","article-title":"Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions","volume":"398","author":"McGinley","year":"2021","journal-title":"Lancet (London, England)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1136\/jnnp-2015-310451","article-title":"Lethal arrhythmia due to fingolimod, a S1P receptor modulator: are we overestimating or underestimating?","volume":"86","author":"Mori","year":"2015","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"B17","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/WCO.0000000000000622","article-title":"Multiple sclerosis: clinical aspects","volume":"31","author":"Oh","year":"2018","journal-title":"Current Opinion in Neurology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s40263-021-00798-w","article-title":"Sphingosine 1-Phosphate receptor modulators for multiple sclerosis","volume":"35","author":"Roy","year":"2021","journal-title":"CNS Drug"},{"key":"B19","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/S1474-4422(13)70102-9","article-title":"Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study","volume":"12","author":"Selmaj","year":"2013","journal-title":"The Lancet. Neurology"},{"key":"B1","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1007\/s00415-017-8636-3","article-title":"Heart rate variability decreases after 3 months of sustained treatment with fingolimod","volume":"264","author":"Vehoff","year":"2017","journal-title":"J. Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"105435","DOI":"10.1016\/j.msard.2024.105435","article-title":"Consensus recommendations for diagnosis and treatment of Multiple Sclerosis: 2023 revision of the MENACTRIMS guidelines","volume":"83","author":"Yamout","year":"2024","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"B21","doi-asserted-by":"publisher","first-page":"795574","DOI":"10.3389\/fimmu.2021.795574","article-title":"Risk for cardiovascular adverse events associated with Sphingosine-1-Phosphate receptor modulators in patients with multiple sclerosis: insights from a pooled analysis of 15 randomised controlled trials","volume":"12","author":"Zhao","year":"2021","journal-title":"Frontiers in Immunology"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1882323\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:29:13Z","timestamp":1787027353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1882323\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":21,"alternative-id":["10.3389\/fphar.2026.1882323"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1882323","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"article-number":"1882323"}}